Table 3.
Peptides used in clinical trials or clinical routine PET diagnosis.
| Peptide/Chelator | Isotope | Target Receptor | Tumour Types | Reference |
|---|---|---|---|---|
| AlF-NOTA-octreotide | [18F] | SSTR a | NET b | [48] |
| DOTA-JR11 (OPS201) | [177Lu] | SSTR a (antagonist) | NET b | [145] |
| DOTANOC | [68Ga] | SSTR-2/3/5 a | NET b | [127] |
| DOTATATE | [68Ga] | SSTR-2 a | NET b | [125] |
| [177Lu]/[90Y] | [143] | |||
| [64Cu] | [132] | |||
| [225Ac] | [144] | |||
| DOTATOC | [68Ga] | SSTR-2/5 a | NET b | [1] |
| [90Y] | [143] | |||
| FET-βAG-TOCA | [18F] | SSTR a | NET b | [136] |
| Gluc-Lys-[18F]FP-TOCA | [18F] | SSTR a | NET b | [134] |
| NODAGA-JR11 (OPS202) | [68Ga] | SSTR-2 a (antagonist) | NET b | [142] |
| SiFAlin-TATE | [18F] | SSTR a | NET b | [139] |
| TETA-octreotide | [64Cu] | SSTR-2 a | NET b | [131] |
| CTT1057 | [18F] | PSMA c | prostate cancer | [166] |
| DCFPyL | [18F] | PSMA c | prostate cancer | [164] |
| EB-PSMA-617 | [177Lu] | PSMA c | prostate cancer | [178] |
| HBED-CC-PSMA (PSMA 11) | [68Ga] | PSMA c | prostate cancer | [85] |
| [18F] | [165,174] | |||
| JK-PSMA-7 | [18F] | PSMA c | prostate cancer | [167] |
| PSMA-I&T | [68Ga] | PSMA c | prostate cancer | [158] |
| [177Lu] | [176] | |||
| PSMA 617 | [177Lu] | PSMA c | prostate cancer | [151] |
| [213Bi] | [181] | |||
| [225Ac] | [182] | |||
| P16-093 | [68Ga] | PSMA c | prostate cancer | [162] |
| PSMA-1007 | [18F] | PSMA c | prostate cancer | [152] |
| THP-PSMA | [68Ga] | PSMA c | prostate cancer | [161] |
| Alfatide | [18F] | integrin αvβ3 | tumour angiogenesis | [197] |
| Alfatide II | [18F] | integrin αvβ3 | tumour angiogenesis | [46] |
| Fluciclatide | [18F] | integrin αvβ3 | tumour angiogenesis | [194] |
| FPPRGD2 | [18F] | integrin αvβ3 | tumour angiogenesis | [196] |
| Galacto-RGD | [18F] | integrin αvβ3 | tumour angiogenesis | [11,188] |
| NODAGA-RGD | [68Ga] | integrin αvβ3 | tumour angiogenesis | [5] |
| NOTA-RGD | [68Ga] | integrin αvβ3 | tumour angiogenesis | [118] |
| NOTA-PRGD2 | [68Ga] | integrin αvβ3 | tumour angiogenesis | [197] |
| RGD-5K | [18F] | integrin αvβ3 | tumour angiogenesis | [193] |
| NOTA-NFB | [68Ga] | chemokine receptor-4 | glioblastoma | [215] |
| Pentixafor | [68Ga] | chemokine receptor-4 | glioblastoma | [211] |
| Pentixather | [177Lu] [90Y] | chemokine receptor-4 | multiple myeloma, diffuse large B cell lymphoma, acute myeloid leukemia | [222] |
| TP3805 | [64Cu] | VPAC1 d | prostate cancer | [230] |
| DOTA-MG0 | [68Ga] | CCK2-R e | MTC f | [233] |
| DTPA-MG0 | [90Y] | CCK2-R e | MTC f | [234] |
| DOTA-PP-F11N | [177Lu] | CCK2-R e | MTC f | [235] |
| CP-18 | [18F] | caspases | apoptosis | [237,238] |
| CB-TE2A-AR06 | [64Cu] | bombesin | prostate cancer | [242] |
| BAY86-7548/RM2 | [68Ga] | bombesin | prostate/breast cancer | [244,245] |
| BZH3 | [68Ga] | bombesin | glioma | [241] |
| SB3 | [68Ga] | bombesin | prostate/breast cancer | [243] |
| DOTA-AE105 | [64Cu] | uPAR g | breast, prostate, bladder cancer | [248] |
| NOTA-AE105 | [68Ga] | uPAR g | breast, prostate, bladder cancer | [249] |
| DOTA-exendin-4 | [68Ga] | GLP-1 h | insulinoma | [253] |
| NOTA-exendin-4 | [68Ga] | GLP-1 h | insulinoma | [255] |
| NODAGA-exendin-4 | [68Ga] | GLP-1 h | Hyperinsulinemic, hypoglycemia | [256] |
a Somatostatin subtype 2 receptor, b neuroendocrine tumours, c prostate-specific membrane antigen, d vasoactive intestinal peptide receptor, e cholecystokinin receptor 2, f medullary thyroid carcinoma, g urokinase-type plasminogen activator receptor, h glucagon-like peptide receptor 1.